Program

P53 W2020 Program

Sunday, May 22
Time	Session/Lecture info
08:30-09:30	Registration
08:30-09:30
09:30-10:30	Opening Session
09:30-09:45	Welcome
09:45-10:30	David Lane, Karolinska Institute Keynote lecture: How does p53 guard the genome?
10:30-11:00	Coffee break
10:30-11:00
11:00-13:00	Session 1: p53 functions (I) Chair: Gigi Lozano
11:00-11:30	Karen Vousden, Crick Institute A role for p53 in controlling cell-cell interactions
11:30-12:00	Giovanni Blandino, Italian National Cancer Institute Regina Elena p53 is a master regulator of non-coding RNA network
12:00-12:30	Lisa Wiesmuller, University of Ulm The tip of an iceberg: replication-associated functions of the tumor suppressor p53
12:30-12:45	Andrei Budanov Regulation of stress-response and longevity by p53-regulated Sestrin in C. elegans
12:45-13:00	Martin Fischer, Fritz Lipmann Institute Stress-responsive RFX7 governs a p53 subnetwork and inhibits AKT and mTORC1
13:00-14:00	Lunch
13:00-14:00
14:00-16:00	Session 2: p53 functions (II) Chair: Yossi Shiloh
14:00-14:30	Kurt Engeland, University of Leipzig With a little help from DREAM: Cell Cycle Regulation by the p53-p21-RB Pathway
14:30-15:00	Batsheva Kerem, The Hebrew University of Jerusalem The molecular basis for the arising replication stress following p53 loss
15:00-15:30	Eli Pikarsky, The Hebrew University of Jerusalem Metabolic functions of p53 in the liver
15:30-15:45	Uri Ben-David, Tel Aviv University Inactivation of p53 drives breast cancer brain metastasis through adaptations of lipid metabolism
15:45-16:00	Carlo De Blasio, IRCM U1194 Montpellier Computational models of p53-associated metabolic networks
16:00-18:30	Social networking & Poster Session I
16:00-18:30

Monday, May 23
Time	Session/Lecture info
08:30-09:00	Registration
08:30-09:00
09:00-10:30	Session 3: p53 structure Chair: Carol Prives
09:00-09:30	Rina Rosenzweig, Weizmann Institute of science Working principles of the Hsp70 chaperone system in cancer biology - an NMR view
09:30-10:00	Zippora Shakked, Weizmann Institute of science Structural studies on reactivation of tumor-related p53 mutants by a small molecule
10:00-10:30	Tali Haran, Technion p53 functionality is encoded in the structural properties of p53 binding sites
10:30-11:15	Coffee break
10:30-11:15
11:15-12:45	Session 4: Mdm2 Chair: Andrei Gudkov
11:15-11:45	Matthias Dobbelstein, University of Goettingen So much more than a p53-antagonist – unexpected roles of Mdm2
11:45-12:15	Carol Prives, Columbia University Unexpected roles for p53, Mdm2 and MdmX in cell survival and cell death
12:15-12:30	Mary Bakhanashvili, Sheba Medical Institute Mitochondrial RNA degradation mediated by p53 protein
12:30-12:45	Alexander Loewer, Technical University Darmstadt Keeping the guardian alert: different upstream regulators enable p53 to differentiate between acute and sustained DNA damage in individual cells
12:45-14:00	Lunch
12:45-14:00
14:00-16:00	Session 5: Mutant p53 in cancer Chair: Karen Vousden
14:00-14:30	David Malkin, University of Toronto Li-Fraumeni syndrome: Harnessing p53 for Clinical Utility
14:30-15:00	Moran Amit , UT MD Anderson Cancer Center TP53 Gain of Function Mutations in Head and Neck Cancer: What’s the Score?
15:00-15:30	Hua Lu, Tulane University School of Medicine VCP Stabilizes Mutant p53 to Promote Pancreatic Cancer Growth
15:30-15:45	Kara Maxwell, University of Pennsylvania Role of the Immune System in Li Fraumeni Syndrome Breast Cancer
15:45-16:00	Ofir Hakim Genomic Retargeting of p53 in Oncogenesis
16:00-18:00	Coffee break & Poster Session II
16:00-18:00
18:00-21:00	Conference Dinner
18:00-21:00

Tuesday, May 24
Time	Session/Lecture info
08:30-09:00	Registration
08:30-09:00
09:00-10:45	Session 6: Mutant p53 functions I Chair: Pierre Hainaut
09:00-09:30	Tomer Cooks, Ben Gurion University Mutant p53 governs microenvironmental dynamics via exosomes
09:30-10:00	Giannino Del Sal, University of Trieste Microenvironment and mechanosignaling in cancer: emerging roles of mut p53
10:00-10:30	Maureen Murphy, The Wistar Institute Identifying important GOF interactors and p53 target genes by the analysis of genetic hypomorphs of p53
10:30-10:45	Luis Martinez, Stony Brook University p53 engages the cGAS/STING cytosolic DNA sensing pathway for tumor suppression
10:45-11:30	Coffee break
10:45-11:30
11:30-13:15	Session 7: Mutant p53 functions II Chair: Laura Attardi
11:30-12:00	Pierre Hainaut, Grenoble University Functional analysis of p53 mutants and genotype-tumor phenotype correlations
12:00-12:30	Moshe Oren, Weizmann Institute of science TP53 mutations in colorectal cancer: different mutant, different disease
12:30-12:45	Dawid Walerych, Polish Academy of Sciences Mutant p53 gain-of-function impact is repressed in the presence of other major oncogenic drivers
12:45-13:00	Tomoo Iwakuma, Children's Mercy Research Institute Stress granule inhibition is a novel vulnerability of mutant p53
13:00-13:15	John Karanicolas, Fox Chase Cancer Center Therapeutic targeting of mutant p53 through structure-based drug design
13:15-14:15	Lunch
13:15-14:15
14:15-15:45	Session 8: p53, microbiome and inflammation I Chair: Valery Krizhanovsky
14:15-14:45	Andrei Gudkov, Roswell Park Comprehensive Cancer Center p53 in control of endogenous ”retrobiome” and inflammation
14:45-15:15	Xin Lu , Oxford University Cancer causing pathogens revisited: a p53-ASPP connection
15:15-15:45	Daniel Menendez, NIH p53 influence on human immune responses to viral infections
15:45-16:15	Coffee break
15:45-16:15
16:15-17:15	Session 9: p53, microbiome and inflammation II Chair: Curtis Harris
16:15-16:45	Yinon Ben-Neriah, The Hebrew University of Jerusalem Lessons from stabilization of WT and mutant p53 in mouse tissues
16:45-17:15	Valery Krizhanovsky, Weizmann Institute of science p53 facilitates chronic lung inflammation
17:15-18:15	Session 10: p53 isoforms and family members Chair: Tomer Cooks
17:15-17:45	Gerry Melino, Tor Vergata University Hippocampal dysgenesis in the p73 mice
17:45-18:15	Curtis Harris, NCI/NIH Regulation of cellular senescence and reprogramming by p53 and its isoforms

Wednesday, May 25
Time	Session/Lecture info
08:30-09:00	Registration
08:30-09:00
09:00-11:00	Session 11: p53 mouse models Chair: Eli Pikarsky
09:00-09:30	Laura Attardi , Stanford University Deconstructing p53 tumor suppression networks
09:30-10:00	Guillermina Lozano, UT MD Anderson Cancer Center Mechanisms of mutant p53 addiction in mouse models of cancer
10:00-10:30	Scott Lowe, Sloan Kettering Institute Catching p53 in the act of tumor suppression
10:30-10:45	James Manfredi, Icahn School of Medicine at Mount Sinai In vivo RNA-seq and ChIP-seq analyses reveal an obligatory role for the C-terminus of p53 in conferring tissue-specific radiation sensitivity
10:45-11:00	Franck Toledo, Institut Curie A mouse model reveals p53 alternatively spliced isoforms as sex-specific tumor suppressors
11:00-11:30	Coffee break
11:00-11:30
11:30-12:45	Session 12: p53 and cancer therapy Chair: Klas Wiman
11:30-12:00	Andreas Strasser, Walter and Eliza Hall Institute of Medical Research Targeting wild-type or mutant p53 for cancer therapy
12:00-12:15	Laura Parrilla-Monge, Stony Brook University Therapeutic ablation of GOF mutp53 in cancer identifies it as critical anti-tumor target
12:15-12:30	Joanna Zawacka-Pankau, Karolinska Institutet Drug repurposing to reactivate p53 protein family members for improved therapy in TP53 mutant cancers
12:30-12:45	Carmit Levi, Tel Aviv University Solar exposed-skin modulate p53-dependent sex specific food-seeking behavior
12:45-14:15	Lunch
12:45-14:15
14:15-15:30	Session 13: Therapeutic targeting of p53 I Chair: Matthias Dobbelstein
14:15-14:45	Galina Selivanova, Karolinska Institutet Restoration of p53 by small molecules sensitise tumors to immune checkpoint blockade
14:45-15:15	Klas Wiman , Karolinska Institutet Pharmacological reactivation of mutant p53: from lab bench to clinic
15:15-15:30	Michael Andreef, UT MD Anderson Cancer Center Activation of p53 by MDM2 and XPO1 inhibition synergizes with BCL-2 inhibition in treatment-resistant AML
15:30-16:15	Coffee break
15:30-16:15
16:15-17:45	Session 14: Therapeutic targeting of p53 II Chair: David Malkin
16:15-16:45	Varda Rotter, Weizmann Institute of science Development of a mutant p53-dependent novel cancer therapy
16:45-17:15	Kanaga Sabapathy, National Cancer Center Singapore Strategies for therapeutic targeting of p53
17:15-17:45	Christine Eischen, Thomas Jefferson University Development of a mutant p53-dependent novel cancer therapy
17:45-18:30	Keynote Lecture
17:45-18:30	Keynote: Arnie Levine , Institute for Advanced Study The p53 Pathway and Immunotherapy and Concluding remarks